New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

For extra enjoyment, she dips her tenders in her mashed potatoes. She says that she lost 200 lbs. "naturally though calorie ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Altimmune's Q1 2025 earnings call highlights breakthroughs in NASH treatments, robust financials with a new $100M credit facility, and imminent Phase ...

Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ETCompany ParticipantsLee Roth - President, Burns McClellan, ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...